Next-generation checkpoints acting on NK and T cells: Data Byte

Following the early success of anti-TIGIT mAbs in clinical development this year, interest in next-generation checkpoints has been on the rise, and there’s reason to believe that checkpoints expressed on both T cells and NK cells could make good targets. 

At least five co-inhibitory receptors act as checkpoints on both immune cell types, dampening cell activation when engaged by ligands. Blocking those receptors with antibodies can relieve immunosuppression and theoretically, unleash both cell types against tumors. ...